AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 6/6 |
Amgen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9,687.00 |
52 Week High | US$14,352.00 |
52 Week Low | US$3,420.00 |
Beta | 0.59 |
1 Month Change | -6.50% |
3 Month Change | -24.56% |
1 Year Change | 164.89% |
3 Year Change | 680.79% |
5 Year Change | n/a |
Change since IPO | 386,092.74% |
Recent News & Updates
Recent updates
Shareholder Returns
AMGN | AR Biotechs | AR Market | |
---|---|---|---|
7D | 3.8% | 0% | 0% |
1Y | 164.9% | 0% | 0% |
Return vs Industry: AMGN exceeded the AR Biotechs industry which returned -4.9% over the past year.
Return vs Market: AMGN underperformed the AR Market which returned 279.7% over the past year.
Price Volatility
AMGN volatility | |
---|---|
AMGN Average Weekly Movement | 5.6% |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in AR Market | 0% |
10% least volatile stocks in AR Market | 0% |
Stable Share Price: AMGN's share price has been volatile over the past 3 months.
Volatility Over Time: AMGN's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
AMGN fundamental statistics | |
---|---|
Market cap | AR$126.25t |
Earnings (TTM) | AR$5.87t |
Revenue (TTM) | AR$24.63t |
21.5x
P/E Ratio5.1x
P/S RatioIs AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMGN income statement (TTM) | |
---|---|
Revenue | US$28.19b |
Cost of Revenue | US$8.42b |
Gross Profit | US$19.78b |
Other Expenses | US$13.06b |
Earnings | US$6.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 12.52 |
Gross Margin | 70.15% |
Net Profit Margin | 23.83% |
Debt/Equity Ratio | 1,036.8% |
How did AMGN perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield68%
Payout RatioDoes AMGN pay a reliable dividends?
See AMGN dividend history and benchmarksAmgen dividend dates | |
---|---|
Ex Dividend Date | May 16 2024 |
Dividend Pay Date | Jun 07 2024 |
Days until Ex dividend | 19 days |
Days until Dividend pay date | 41 days |
Does AMGN pay a reliable dividends?
See AMGN dividend history and benchmarks